Huaping Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huaping Zheng has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Deng
Department of Respiratory and Critical Care Medicine, Center for High Altitude Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
5 shared publications Jingqiu Cheng
Department of Respiratory and Critical Care Medicine, Center for High Altitude Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
3 shared publications- Jürgen Brosius
Department of High Altitude Medicine, Center for High Altitude Medicine, College of Life Sciences, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
3 shared publications Ting Zhang
Department of High Altitude Medicine Center For High Altitude Medicine College of Life Sciences National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan People's Republic of China
3 shared publicationsChen Zhang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China
2 shared publicationsChengcheng Yue
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Wiley in Advanced Science
- p. e77451
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Metabolic dysfunction‐associated steatotic liver disease (MASLD) poses an increasing threat to global public health. Currently approved drugs for MASLD, such as resmetirom and semaglutide, have demonstrated clinical efficacy. However, their use is associated with notable adverse effects, including serious gastrointestinal reactions, metabolic and nutritional disturbances, and renal or urinary system disorders. The present study established that the expression levels of a liver‐secreted protein, the “out at first homolog” ( Oaf ) gene product, are closely associated with metabolic disorders in humans and mice. In a high‐fat diet (HD) feeding mouse model, Oaf ‐deficiency exacerbated hepatic lipid accumulation, whereas intraperitoneal injection of OAF protein ameliorated the development of MASLD. Mechanistically, OAF binds to SCPX and acts as a chaperone, preventing SCPX from degradation by SIAH1‐mediated ubiquitination. This stabilizes SCPX and increases its abundance, thereby enhancing cholesterol transport, lipid esterification, and lipid excretion, while inhibiting lipid biosynthesis. In mice, deficiency of either Oaf or Scpx reduced these effects. Collectively, our findings identify OAF as a novel therapeutic target for the treatment of MASLD and provide a rationale for further drug development targeting human fatty liver diseases.
- 29 August 2026
- Published by Wiley in Advanced Science
- p. e77451
Open AccessOAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Metabolic dysfunction‐associated steatotic liver disease (MASLD) poses an increasing threat to global public health. Currently approved drugs for MASLD, such as resmetirom and semaglutide, have demonstrated clinical efficacy. However, their use is associated with notable adverse effects, including serious gastrointestinal reactions, metabolic and nutritional disturbances, and renal or urinary system disorders. The present study established that the expression levels of a liver‐secreted protein, the “out at first homolog” ( Oaf ) gene product, are closely associated with metabolic disorders in humans and mice. In a high‐fat diet (HD) feeding mouse model, Oaf ‐deficiency exacerbated hepatic lipid accumulation, whereas intraperitoneal injection of OAF protein ameliorated the development of MASLD. Mechanistically, OAF binds to SCPX and acts as a chaperone, preventing SCPX from degradation by SIAH1‐mediated ubiquitination. This stabilizes SCPX and increases its abundance, thereby enhancing cholesterol transport, lipid esterification, and lipid excretion, while inhibiting lipid biosynthesis. In mice, deficiency of either Oaf or Scpx reduced these effects. Collectively, our findings identify OAF as a novel therapeutic target for the treatment of MASLD and provide a rationale for further drug development targeting human fatty liver diseases.
- Open Access
- 28 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Avian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment
Human obesity is the fifth leading cause of global mortality. Fat mass loss and maintenance are central challenges for obesity management. In contrast, birds exhibit modest weight gain and limited fat accumulation due to rapid fat utilization as flight fuel. The physiology of this adaptation remained a mystery for a century. Here we show that cross-species single-nucleus RNA-sequencing analysis revealed high GCGR expression levels in avian adipocytes, while minimal in the adipose tissue of other vertebrates. Avian GCGR employs a unique rapid fat utilization mechanism for retaining a light body. Avian GCGR or other constitutively active GCGR variants (human GCGRH339R) expressed in white adipose tissue of male mice with obesity effectively promoted fat mobilization and sustained body weight loss, with decreased food intake partially contributing to the observed weight reduction. We suggest that avian GCGR plays this crucial role for fat utilization and may offer therapeutic potential for human obesity.
- 28 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessAvian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment
Human obesity is the fifth leading cause of global mortality. Fat mass loss and maintenance are central challenges for obesity management. In contrast, birds exhibit modest weight gain and limited fat accumulation due to rapid fat utilization as flight fuel. The physiology of this adaptation remained a mystery for a century. Here we show that cross-species single-nucleus RNA-sequencing analysis revealed high GCGR expression levels in avian adipocytes, while minimal in the adipose tissue of other vertebrates. Avian GCGR employs a unique rapid fat utilization mechanism for retaining a light body. Avian GCGR or other constitutively active GCGR variants (human GCGRH339R) expressed in white adipose tissue of male mice with obesity effectively promoted fat mobilization and sustained body weight loss, with decreased food intake partially contributing to the observed weight reduction. We suggest that avian GCGR plays this crucial role for fat utilization and may offer therapeutic potential for human obesity.
- Open Access
- 17 September 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-19
GPR15 differentially regulates the effects of cigarette smoke exposure on Crohn’s disease and ulcerative colitis
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic disorder characterized by gastrointestinal inflammation. Cigarette smoke is a well-established risk factor for the development and exacerbation of CD while exerting a paradoxical protective effect against the onset of UC. The exact mechanisms by which cigarette smoke influences IBD, as well as the opposite effects in UC and CD, have long remained unexplained. Here, we demonstrated the detrimental impact of cigarette smoke on CD progression while highlighting its beneficial effects on UC, as evidenced by analyses of human sample data. Mouse models of CD and UC exposed to cigarette smoke presented phenotypes consistent with those observed in human disease. GPR15, previously reported to direct regulatory T (Treg) cell colon homing, was upregulated in the colon tissues of both chemically induced colitis models after smoke exposure. Importantly, Gpr15 deletion ameliorated smoke-induced CD while increasing UC severity in mice. Furthermore, our study revealed that cigarette smoke mediated GPR15 to amplify colonic T helper type 17 (Th17) cell populations, thereby worsening the adverse effects of smoking on CD in mouse models. Moreover, cigarette smoke induced an increase in Treg cells through GPR15, which contributed to mitigating its impact on UC in mouse models. Moreover, in cigarette smoke-exposed CD and UC model mice, C57BL/6JGpt-Tg (human GPR15) transgenic mice presented phenotypes opposite those of Gpr15-deficient mice. Overall, our study offers mechanistic insights into the role of cigarette smoke-induced GPR15+ T cells in mediating the divergent effects of smoking on UC and CD.
- 17 September 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-19
Open AccessGPR15 differentially regulates the effects of cigarette smoke exposure on Crohn’s disease and ulcerative colitis
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic disorder characterized by gastrointestinal inflammation. Cigarette smoke is a well-established risk factor for the development and exacerbation of CD while exerting a paradoxical protective effect against the onset of UC. The exact mechanisms by which cigarette smoke influences IBD, as well as the opposite effects in UC and CD, have long remained unexplained. Here, we demonstrated the detrimental impact of cigarette smoke on CD progression while highlighting its beneficial effects on UC, as evidenced by analyses of human sample data. Mouse models of CD and UC exposed to cigarette smoke presented phenotypes consistent with those observed in human disease. GPR15, previously reported to direct regulatory T (Treg) cell colon homing, was upregulated in the colon tissues of both chemically induced colitis models after smoke exposure. Importantly, Gpr15 deletion ameliorated smoke-induced CD while increasing UC severity in mice. Furthermore, our study revealed that cigarette smoke mediated GPR15 to amplify colonic T helper type 17 (Th17) cell populations, thereby worsening the adverse effects of smoking on CD in mouse models. Moreover, cigarette smoke induced an increase in Treg cells through GPR15, which contributed to mitigating its impact on UC in mouse models. Moreover, in cigarette smoke-exposed CD and UC model mice, C57BL/6JGpt-Tg (human GPR15) transgenic mice presented phenotypes opposite those of Gpr15-deficient mice. Overall, our study offers mechanistic insights into the role of cigarette smoke-induced GPR15+ T cells in mediating the divergent effects of smoking on UC and CD.
- Top Cited PapersOpen Access
- 20 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity
G protein-coupled sphingosine-1-phosphate receptor 1 (S1PR1), a drug target for inflammatory bowel disease (IBD), enables immune cells to egress from lymph nodes, but the treatment increases the risk of immunosuppression. The functional signaling pathway triggered by S1PR1 activation in endothelial cells and its therapeutic application remains unclear. Here, we showed that S1PR1 is highly expressed in endothelial cells of IBD patients and positively correlated with endothelial markers. Gi-biased agonist-SAR247799 activated S1PR1 and reversed pathology in male mouse and organoid IBD models by protecting the integrity of the endothelial barrier without affecting immune cell egress. Cryo-electron microscopy structure of S1PR1-Gi signaling complex bound to SAR247799 with a resolution of 3.47 Å revealed the recognition mode for the biased ligand. With the efficacy of SAR247799 in treating other endothelial dysfunction-associated inflammatory diseases, our study offers mechanistic insights into the Gi-biased S1PR1 agonist and represents a strategy for endothelial dysfunction-associated disease treatment.
- 20 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Top Cited PapersOpen AccessS1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity
G protein-coupled sphingosine-1-phosphate receptor 1 (S1PR1), a drug target for inflammatory bowel disease (IBD), enables immune cells to egress from lymph nodes, but the treatment increases the risk of immunosuppression. The functional signaling pathway triggered by S1PR1 activation in endothelial cells and its therapeutic application remains unclear. Here, we showed that S1PR1 is highly expressed in endothelial cells of IBD patients and positively correlated with endothelial markers. Gi-biased agonist-SAR247799 activated S1PR1 and reversed pathology in male mouse and organoid IBD models by protecting the integrity of the endothelial barrier without affecting immune cell egress. Cryo-electron microscopy structure of S1PR1-Gi signaling complex bound to SAR247799 with a resolution of 3.47 Å revealed the recognition mode for the biased ligand. With the efficacy of SAR247799 in treating other endothelial dysfunction-associated inflammatory diseases, our study offers mechanistic insights into the Gi-biased S1PR1 agonist and represents a strategy for endothelial dysfunction-associated disease treatment.
- Top Cited PapersOpen Access
- 30 January 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-18
Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism
The intestinal microbiota has been associated with host immunity as well as psoriasis; however, the mechanism of intestinal microbiota regulating psoriasis needs to be demonstrated systematically. Here, we sought to examine its role and mechanism of action in the pathogenesis of psoriasis. We found that the severity of psoriasis-like skin phenotype was accompanied by changes in the composition of the intestinal microbiota. We performed co-housing and fecal microbial transplantation (FMT) experiments using the K14-VEGF transgenic mouse model of psoriasis and demonstrated that the transfer of intestinal microbiota from mice with severe psoriasis-like skin phenotype exacerbated psoriasiform skin inflammation in mice with mild symptoms, including increasing the infiltration and differentiation of Th17, and increased the abundance of Prevotella, while decreasing that of Parabacteroides distasonis, in the colon. These alterations affected fatty acid metabolism, increasing the abundance of oleic and stearic acids. Meanwhile, gentamicin treatment significantly reduced the abundance of Prevotella and alleviated the psoriasis-like symptoms in both K14-VEGF mice and imiquimod (IMQ)-induced psoriasis-like mice. Indeed, administration of oleic and stearic acids exacerbated psoriasis-like symptoms and increased Th17 and monocyte-derived dendritic cell infiltration in the skin lesion areas in vivo, as well as increased the secretion of IL-23 by stimulating DCs in vitro. At last, we found that, treatment of PDE-4 inhibitor alleviated psoriasis-like phenotype of K14-VEGF mice accompanied by the recovery of intestinal microbiota, including the decrease of Prevotella and increase of Parabacteroides distasonis. Overall, our findings reveal that the intestinal microbiota modulates host metabolism and psoriasis-like skin inflammation in mice, suggesting a new target for the clinical diagnosis and treatment of psoriasis.
- 30 January 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-18
Top Cited PapersOpen AccessIntestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism
The intestinal microbiota has been associated with host immunity as well as psoriasis; however, the mechanism of intestinal microbiota regulating psoriasis needs to be demonstrated systematically. Here, we sought to examine its role and mechanism of action in the pathogenesis of psoriasis. We found that the severity of psoriasis-like skin phenotype was accompanied by changes in the composition of the intestinal microbiota. We performed co-housing and fecal microbial transplantation (FMT) experiments using the K14-VEGF transgenic mouse model of psoriasis and demonstrated that the transfer of intestinal microbiota from mice with severe psoriasis-like skin phenotype exacerbated psoriasiform skin inflammation in mice with mild symptoms, including increasing the infiltration and differentiation of Th17, and increased the abundance of Prevotella, while decreasing that of Parabacteroides distasonis, in the colon. These alterations affected fatty acid metabolism, increasing the abundance of oleic and stearic acids. Meanwhile, gentamicin treatment significantly reduced the abundance of Prevotella and alleviated the psoriasis-like symptoms in both K14-VEGF mice and imiquimod (IMQ)-induced psoriasis-like mice. Indeed, administration of oleic and stearic acids exacerbated psoriasis-like symptoms and increased Th17 and monocyte-derived dendritic cell infiltration in the skin lesion areas in vivo, as well as increased the secretion of IL-23 by stimulating DCs in vitro. At last, we found that, treatment of PDE-4 inhibitor alleviated psoriasis-like phenotype of K14-VEGF mice accompanied by the recovery of intestinal microbiota, including the decrease of Prevotella and increase of Parabacteroides distasonis. Overall, our findings reveal that the intestinal microbiota modulates host metabolism and psoriasis-like skin inflammation in mice, suggesting a new target for the clinical diagnosis and treatment of psoriasis.
- Open Access
- 21 July 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (7) , 1-13
SerpinB7 deficiency contributes to development of psoriasis via calcium-mediated keratinocyte differentiation dysfunction
Defective execution of proteases and protease inhibitors that mediate abnormal signaling cascades is emerging as a key contributor to skin diseases, such as psoriasis. SerpinB7 is identified as a skin-specific endogenous protease inhibitor, but the role and underlying mechanism in psoriasis are poorly understood. Here we found that SerpinB7 is highly expressed in psoriatic keratinocytes of patients and imiquimod-induced psoriatic lesions in mice. SerpinB7-/- mice showed abnormal epidermal barrier integrity and skin architecture in homeostasis, and aggravated psoriatic lesion with inhibiting terminal differentiation and increasing inflammatory cells infiltration compared to SerpinB7+/+ mice after Imiquimod treatment. Mechanistically, SerpinB7 deficiency results in excessive proliferation and impaired differentiation, as well as increased chemokines and antimicrobial peptide expression in normal human epidermal keratinocyte and mouse primary keratinocyte. Transcriptomics and proteomics results showed that the SeprinB7 deficiency affected keratinocyte differentiation and proinflammatory cytokines, possibly by affecting the calcium ion channel-related proteins. Notably, we demonstrated that SerpinB7 deficiency prevented the increase in intracellular Ca2+ influx, which was partly eliminated by the intracellular Ca2+ chelator BAPTA-AM. Our findings first described the critical role of SerpinB7 in the regulation of keratinocyte differentiation and psoriatic microenvironment mediated via keratinocytes' intracellular calcium flux, proposing a new candidate for therapeutic targets in psoriasis.
- 21 July 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (7) , 1-13
Open AccessSerpinB7 deficiency contributes to development of psoriasis via calcium-mediated keratinocyte differentiation dysfunction
Defective execution of proteases and protease inhibitors that mediate abnormal signaling cascades is emerging as a key contributor to skin diseases, such as psoriasis. SerpinB7 is identified as a skin-specific endogenous protease inhibitor, but the role and underlying mechanism in psoriasis are poorly understood. Here we found that SerpinB7 is highly expressed in psoriatic keratinocytes of patients and imiquimod-induced psoriatic lesions in mice. SerpinB7-/- mice showed abnormal epidermal barrier integrity and skin architecture in homeostasis, and aggravated psoriatic lesion with inhibiting terminal differentiation and increasing inflammatory cells infiltration compared to SerpinB7+/+ mice after Imiquimod treatment. Mechanistically, SerpinB7 deficiency results in excessive proliferation and impaired differentiation, as well as increased chemokines and antimicrobial peptide expression in normal human epidermal keratinocyte and mouse primary keratinocyte. Transcriptomics and proteomics results showed that the SeprinB7 deficiency affected keratinocyte differentiation and proinflammatory cytokines, possibly by affecting the calcium ion channel-related proteins. Notably, we demonstrated that SerpinB7 deficiency prevented the increase in intracellular Ca2+ influx, which was partly eliminated by the intracellular Ca2+ chelator BAPTA-AM. Our findings first described the critical role of SerpinB7 in the regulation of keratinocyte differentiation and psoriatic microenvironment mediated via keratinocytes' intracellular calcium flux, proposing a new candidate for therapeutic targets in psoriasis.
- Open Access
- 23 December 2021
- Published by Springer Nature in EMBO Reports
- Vol. 23 (3) , e53246
GPR15–C10ORF99 functional pairing initiates colonic Treg homing in amniotes
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 23 December 2021
- Published by Springer Nature in EMBO Reports
- Vol. 23 (3) , e53246
Open AccessGPR15–C10ORF99 functional pairing initiates colonic Treg homing in amniotes
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.